- ¥1tn
- ¥997bn
- ¥497bn
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Deals of the day-Mergers and acquisitions
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln
Notice Regarding Agreement To Acquire Shares Of Uk Biopharmaceutical Company Orchard Therapeutics PLC
Brief: Kyowa Kirin Co Says Tenapanor For Hyperphosphatemia Approved In Japan
Table: Kyowa Kirin -6-MTH group results (IFRS)
Brief: Kyowa Kirin Designs New North American Headquarters
Table: Kyowa Kirin -Q1 group results (IFRS)
Table: Kyowa Kirin -2022 parent results
Table: Kyowa Kirin -2022 group results (IFRS)
MEI Pharma tumbles on discontinuing lead drug development
MEI Pharma winds down cancer drug program outside Japan, shares slip
Table: Kyowa Kirin -2022 group forecast(IFRS)
Brief: MEI Pharma And Kyowa Kirin Announce Discontinuation Of Zandelisib Development Outside Of Japan
Brief: Kyowa Kirin And MEI Pharma Announce Topline Data From Phase 2 MIRAGE Study Evaluating Zandelisib In Patients With Indolent B-Cell Non-Hodgkin's Lymphoma In Japan
Table: Kyowa Kirin -9-MTH group results (IFRS)
Brief: Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission Of New Drug Application For Tenapanor For Hyperphosphatemia In Japan
Media: Grünenthal leads race for Kyowa Kirin's international assets - Bloomberg News
Table: Kyowa Kirin -6-MTH group results (IFRS)